Biological safety cabinets and cell incubators for hematologic malignancies

LEUKEMIA, LYMPHOMA & MYELOMA EVALUATION

Advanced Blood Cancer Care in China

Blood cancers—including leukemia, lymphoma, and multiple myeloma—affect the bone marrow and immune system. When standard chemotherapy stops working or cancer returns, patients need advanced options. China has become a global leader in cellular immunotherapy, performing more CAR-T cell infusions and half-matched bone marrow transplants than any other country, offering real hope and lasting remissions for difficult cases.

  • Leukemia, Lymphoma & Multiple Myeloma at Any Stage
  • Cancer That Has Returned or Resisted Prior Chemotherapy
  • Patients Seeking Advanced Living Cell Therapy (CAR-T) or Transplant
  • World-Leading Cell Therapy Units with Ultra-Clean Sterile Rooms
  • Experienced Specialists with Thousands of Successful Cell Infusions
  • Dedicated English-Speaking Medical Coordinators at Your Bedside

ADVANCED TREATMENT OPTIONS

Key Blood Cancer Treatments

World-leading CAR-T cell therapy, haploidentical BMT, and targeted antibody biologics.

CAR-T Cell Therapy

Your own immune cells are collected, trained in a lab to recognize and attack blood cancer cells, and returned to your body to hunt down tumors.
Learn More

Bone Marrow Transplant

Using the world-renowned "Beijing Protocol", almost any family member (even a 50% match) can safely donate stem cells, eliminating the wait for an exact donor match.
Learn More

Targeted Antibody Biologics

Smart medications that stick directly to cancer cells like homing beacons, helping destroy the cancer while leaving healthy blood cells unharmed.
Learn More

WHY CHOOSE US

Why Choose China for Blood Cancer

Direct access to China's leading hematology institutes and CAR-T clinical research hubs.

You are not directed to an unvetted broker network. We connect you directly with China’s premier Grade 3A national hematology institutes that treat the world’s largest volumes of relapsed and refractory leukemia, lymphoma, and multiple myeloma. Patients gain direct access to advanced CAR-T cellular therapies, world-renowned half-matched stem cell transplants (Beijing Protocol), and innovative targeted antibodies often available years ahead of international approvals.

Before you make any travel arrangements, a specialized hematology tumor board evaluates your complete pathology, flow cytometry, and genetic panel to confirm clinical eligibility and recommend a clear protocol. All medical care is billed directly by accredited public tertiary hospitals under transparent, published fee schedules, with continuous English bedside coordination from admission to post-discharge care.

HOW IT WORKS

4 Steps to Treatment in China

A simple, step-by-step process from initial record review to your arrival and treatment in China.

01. Submit Records Online

Upload existing pathology reports, biomarker NGS profiles, and imaging scans through our secure clinical intake portal.

02. Pre-Screen & Doctor Match

Clinical eligibility and contraindication screening, matching your specific case with China's foremost oncology chiefs.

03. Doctor Consultation

One-on-one remote video consultation or written multidisciplinary assessment to confirm treatment protocol before travel.

04. Travel to China & Care

Expedited medical visa support, priority hospital admission, dedicated bilingual bedside escorts, and continuum follow-up.

PATIENT FAQS

Frequently Asked Questions

Key clinical, financial, and logistical insights for international patients considering care in China.
Patients with relapsed or refractory B-cell acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma who have progressed after standard therapies can be evaluated for CD19, CD22, or BCMA directed CAR-T cells.
The Beijing Protocol is a globally recognized half-matched (haploidentical) stem cell transplantation method allowing parents, children, or siblings who are only a 50% HLA match to successfully serve as donors with outcomes equal to identical donor matches.
Patients generally stay 3 to 4 weeks, including cell collection, bridging therapy if necessary, infusion, and careful monitoring in sterile laminar flow rooms.
Tertiary hematology centers maintain dedicated intensive care units and standardized protocols to promptly manage cytokine release syndrome (CRS) and neurotoxicity.

CONFIDENTIAL CASE EVALUATION

Start with a Confidential Clinical Case Review

Submit your basic case details below for an initial eligibility review. Our medical team coordinates directly with chief oncologists at top Chinese cancer centers, returning a preliminary assessment and roadmap within 24–48 hours.

✓ Free initial triage  •  ✓ Direct specialist coordination  •  ✓ 100% Confidential

    Blood Cancer

    There is Only One Thing In The World I Want
    And That Is Hospital.

    Copyright © 2026 PBM Infotech